Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.4
4.5
Journals
Microorganisms
Special Issues
State-of-the-Art Clinical Microbiology Technology in Korea
share announcement

State-of-the-Art Clinical Microbiology Technology in Korea

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Medical Microbiology".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 8794

Special Issue Editor

Dr. Garima Sharma

E-Mail Website
Guest Editor
Department of Biomedical Science & Institute of Bioscience and Biotechnology, Kangwon National University, Chuncheon 24341, Republic of Korea
Interests: vaccine; SARS-CoV-2; infectious disease

Special Issue Information

Dear Colleagues,

Since the beginning of 2020, the spread of SARS-CoV2 has challenged the scientific community to develop more advanced, accurate, and rapid diagnostic and therapeutic approaches to treat microbial infections. Although studies in clinical microbiology have grown substantially over the last few years, a greater focus on strategizing novel and improved antimicrobial agents against pathogenic microorganisms is needed. Defining and monitoring state-of-the-art and emerging technologies in clinical microbiology is of the utmost importance.

This Special Issue covers the current developments and modern technologies in diagnosis, therapy, device, methods, mechanisms, etc., to meet the current demands in the fight against emerging microbes-associated infections and diseases. It is anticipated that these emerging antimicrobial technologies will facilitate the world to successfully counteract pandemic outbursts in the future in a cost-effective and time-effective manner.

Dr. Garima Sharma
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • clinical microbiology
  • interaction of microbes and disease
  • antimicrobial agents
  • diagnosis
  • therapeutic agents
  • devices
  • methodologies

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

3 pages, 176 KiB  
Editorial
State-of-the-Art Clinical Microbiology in South Korea: Current Trends and Future Prospects
by Garima Sharma and Jin-Chul Kim
Microorganisms 2022, 10(1), 174; https://doi.org/10.3390/microorganisms10010174 - 14 Jan 2022
Viewed by 1512
Abstract
Researchers and clinicians have repeatedly explored the clinical aspects of microorganisms because the human body is inhabited by several different microbial species and their strains [...] Full article
(This article belongs to the Special Issue State-of-the-Art Clinical Microbiology Technology in Korea)

Research

Jump to: Editorial, Review

13 pages, 2560 KiB  
Article
Insights into the Antibacterial Activity of Prolactin-Inducible Protein against the Standard and Environmental MDR Bacterial Strains
by Mohd Yousuf, Asghar Ali, Parvez Khan, Farah Anjum, Abdelbaset Mohamed Elasbali, Asimul Islam, Dharmendra Kumar Yadav, Alaa Shafie, Qazi Mohd. Rizwanul Haque and Md. Imtaiyaz Hassan
Microorganisms 2022, 10(3), 597; https://doi.org/10.3390/microorganisms10030597 - 9 Mar 2022
Cited by 5 | Viewed by 2032
Abstract
Background: Prolactin inducible protein (PIP) is a small secretary glycoprotein present in most biological fluids and contributes to various cellular functions, including cell growth, fertility, antitumor, and antifungal activities. Objectives: The present study evaluated the antibacterial activities of recombinant PIP against multiple broad-spectrum [...] Read more.
Background: Prolactin inducible protein (PIP) is a small secretary glycoprotein present in most biological fluids and contributes to various cellular functions, including cell growth, fertility, antitumor, and antifungal activities. Objectives: The present study evaluated the antibacterial activities of recombinant PIP against multiple broad-spectrum MDR bacterial strains. Methods: The PIP gene was cloned, expressed and purified using affinity chromatography. Disk diffusion, broth microdilution, and growth kinetic assays were used to determine the antibacterial activities of PIP. Results: Disk diffusion assay showed that PIP has a minimum and maximum zone of inhibition against E. coli and P. aeruginosa, respectively, compared to the reference drug ampicillin. Furthermore, growth kinetics studies also suggested that PIP significantly inhibited the growth of E. coli and P. aeruginosa. The minimum inhibitory concentration of PIP was 32 µg/mL for E. coli (443), a standard bacterial strain, and 64 µg/mL for Bacillus sp. (LG1), an environmental multidrug-resistant (MDR) strain. The synergistic studies of PIP with ampicillin showed better efficacies towards selected bacterial strains having MDR properties. Conclusion: Our findings suggest that PIP has a broad range of antibacterial activities with important implications in alleviating MDR problems. Full article
(This article belongs to the Special Issue State-of-the-Art Clinical Microbiology Technology in Korea)
►▼ Show Figures

Figure 1

Review

Jump to: Editorial, Research

35 pages, 2008 KiB  
Review
Varied Composition and Underlying Mechanisms of Gut Microbiome in Neuroinflammation
by Rai Khalid Farooq, Widyan Alamoudi, Amani Alhibshi, Suriya Rehman, Ashish Ranjan Sharma and Fuad A. Abdulla
Microorganisms 2022, 10(4), 705; https://doi.org/10.3390/microorganisms10040705 - 25 Mar 2022
Cited by 11 | Viewed by 4597
Abstract
The human gut microbiome has been implicated in a host of bodily functions and their regulation, including brain development and cognition. Neuroinflammation is a relatively newer piece of the puzzle and is implicated in the pathogenesis of many neurological disorders. The microbiome of [...] Read more.
The human gut microbiome has been implicated in a host of bodily functions and their regulation, including brain development and cognition. Neuroinflammation is a relatively newer piece of the puzzle and is implicated in the pathogenesis of many neurological disorders. The microbiome of the gut may alter the inflammatory signaling inside the brain through the secretion of short-chain fatty acids, controlling the availability of amino acid tryptophan and altering vagal activation. Studies in Korea and elsewhere highlight a strong link between microbiome dynamics and neurocognitive states, including personality. For these reasons, re-establishing microbial flora of the gut looks critical for keeping neuroinflammation from putting the whole system aflame through probiotics and allotransplantation of the fecal microbiome. However, the numerosity of the microbiome remains a challenge. For this purpose, it is suggested that wherever possible, a fecal microbial auto-transplant may prove more effective. This review summarizes the current knowledge about the role of the microbiome in neuroinflammation and the various mechanism involved in this process. As an example, we have also discussed the autism spectrum disorder and the implication of neuroinflammation and microbiome in its pathogenesis. Full article
(This article belongs to the Special Issue State-of-the-Art Clinical Microbiology Technology in Korea)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop